Employees: 77
Size Inventiva (IVA.PA) is a France Health Care company (Biotechnology) with a market value of $763M, the 152nd largest of 206 France companies the cockpit tracks. Shares closed at €2.91 on 18 Nov 2026.
Performance Over six months the shares fell 36.0%, against -12.2% for the median peer and -2.1% for the France market (cap-weighted) — 5th lowest of 19 in its peer set.
Growth Revenue fell 99.6% over the last twelve months (peer median +15.1%); the operating margin is -307,063.3% (peer median -84.7%).
Valuation It trades at 12,169.8× enterprise value to sales against a peer median of 6.6× (most expensive of 17).
Next results Next results expected around 31 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | €49,000 | €4.48M | €9.20M | €17.5M | €12.2M |
| Revenue growth | — | -51% | -47% | +44% | — |
| Gross profit | -€2.56M | €1.57M | €5.61M | €14.9M | n/a |
| EBITDA | -€148M | -€133M | -€95.9M | -€105M | -€61.0M |
| Net income | -€248M | -€354M | -€184M | -€110M | -€54.3M |
| Free cash flow | -€110M | -€105M | -€86.3M | -€82.2M | -€45.5M |
| Capital expenditure | €358,000 | €247,000 | €333,000 | €540,000 | €561,000 |
| Total debt | n/a | €59.4M | €54.3M | €37.4M | €34.5M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | IVA.PA | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +0.3% | -6.9% | 7th highest of 21 |
| 6-month return | -36.0% | -12.2% | 5th lowest of 19 |
| Distance from 52-week high | -53.1% | -44.9% | 6th lowest of 21 |
| Revenue growth (TTM) | -99.6% | +15.1% | lowest of 15 |
| Operating margin | -307,063.3% | -84.7% | lowest of 17 |
| EV / Sales | 12,169.8× | 6.6× | most expensive of 17 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Inventiva IVA.PA | France | $763M | -36% | -100% | -307,063% | 12,169.8× | n/a | n/a |
| Nanjing Leads Biolabs 9887.HK | Hong Kong | $764M | -50% | n/a | -108% | 21.1× | n/a | n/a |
| Syndax Pharmaceuticals SNDX | United States | $771M | -57% | +160% | -62% | 3.2× | n/a | n/a |
| Monte Rosa Therapeutics GLUE | United States | $775M | -51% | -61% | -214% | 3.3× | n/a | n/a |
| Wuhan Keqian Biology 688526.SS | China | $780M | -24% | -22% | 20% | 4.4× | 7.8% | +2.4% |
| Aura Biosciences AURA | United States | $743M | -4% | n/a | n/a | n/a | n/a | n/a |
| Beijing SL Pharmaceutical 002038.SZ | China | $736M | -20% | -4% | -119% | 6.9× | -13.5% | -10.9% |
| Apnimed APMD | United States | $726M | n/a | +380% | -140% | 10.8× | n/a | n/a |
| R&G PharmaStudies 301333.SZ | China | $722M | -11% | +21% | 11% | 3.4× | 17.3% | +11.8% |
| MeiraGTx MGTX | United States | $813M | -13% | +1,366% | 44% | 1.9× | n/a | n/a |
| Shaanxi Micot Pharmaceutical Technology 2335.HK | Hong Kong | $715M | n/a | n/a | n/a | n/a | n/a | n/a |
| Attovia Therapeutics ATTO | United States | $710M | +1,325% | n/a | -5,945% | 220.7× | n/a | n/a |
| Solid Biosciences SLDB | United States | $709M | -2% | n/a | n/a | n/a | n/a | n/a |
| Prime Medicine PRME | United States | $695M | +35% | +18% | -2,584% | 105.4× | n/a | n/a |
| Oxford BioMedica OXB.L | United Kingdom | $841M | -15% | +16% | -18% | 4.1× | n/a | n/a |
| Anhui Wanbang Pharmaceutical Technology 301520.SZ | China | $684M | +74% | -15% | -8% | 14.7× | 44.8% | +14.7% |
| Kura Oncology KURA | United States | $674M | -29% | -24% | -394% | 2.6× | n/a | n/a |
| Verastem VSTM | United States | $866M | +66% | +650% | -194% | 8.2× | n/a | n/a |
| Steminent Biotherapeutics 7729.TWO | Taiwan | $668M | +292% | n/a | n/a | n/a | n/a | n/a |
| Alphamab Oncology 9966.HK | Hong Kong | $666M | -38% | -32% | -38% | 6.7× | n/a | n/a |
| Peptidream 4587.T | Japan | $878M | -3% | +14% | -18% | 6.6× | n/a | n/a |